Risk Profile Improvements

  • Going Concern (unchanged) — Substantial doubt about ability to continue as going concern persists; cash runway extended to Q3 2026 but additional funding required thereafter.
NASDAQ: MCRB Seres Therapeutics, Inc. 10-K

Seres pauses SER-155 Phase 2, pivots to inflammatory diseases, cuts 56% of workforce

Filed March 12, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 13, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade MCRB commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov View full financials on EDGAR ↗

Generated by AI · Jun 5, 2026 4:08 AM